Rivaroxaban: an oral direct inhibitor of factor Xa

MP Gulseth, J Michaud… - American Journal of Health …, 2008 - academic.oup.com
Purpose. The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban …
被引用次数：131 相关文章

Rivaroxaban: an oral direct inhibitor of factor Xa.

MP Gulseth, J Michaud, EA Nutescu - American Journal of Health …, 2008 - europepmc.org
Purpose The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban …

Rivaroxaban: an oral direct inhibitor of factor Xa

MP Gulseth, J Michaud, EA Nutescu - American Journal of Health …, 2008 - go.gale.com
Purpose. The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban …

[引用][C] Rivaroxaban: An oral direct inhibitor of factor Xa

MP Gulseth, J Michaud, EA Nutescu - American Journal of Health …, 2008 - cir.nii.ac.jp
Rivaroxaban: An oral direct inhibitor of factor Xa | CiNii Research CiNii 国立情報学研究所 学術
情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …

Rivaroxaban: an oral direct inhibitor of factor Xa

MP Gulseth, J Michaud… - American journal of …, 2008 - pubmed.ncbi.nlm.nih.gov
Purpose The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban …
[PDF] kau.edu.sa

[PDF][PDF] Rivaroxaban: An oral direct inhibitor of factor Xa

MP GULSETH, J MICHAUD, EA NUTESCU - Am J Health-Syst Pharm, 2008 - kau.edu.sa
Purpose. The mechanism of action, phar macodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of riva roxaban …

Rivaroxaban: An oral direct inhibitor of factor Xa.

MP Gulseth, J Michaud… - American Journal of …, 2008 - search.ebscohost.com
Purpose. The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban …
[PDF] researchgate.net

[PDF][PDF] Rivaroxaban: An oral direct inhibitor of factor Xa

MP GULSETH, J MICHAUD… - Am J Health-Syst …, 2008 - researchgate.net
Purpose. The mechanism of action, phar macodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of riva roxaban …
[PDF] kau.edu.sa

[PDF][PDF] Rivaroxaban: An oral direct inhibitor of factor Xa

MP GULSETH, J MICHAUD, EA NUTESCU - Am J Health-Syst Pharm, 2008 - kau.edu.sa
Purpose. The mechanism of action, phar macodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of riva roxaban …

[引用][C] Rivaroxaban: An oral direct inhibitor of factor Xa

MP GULSETH, J MICHAUD… - American …, 2008 - American Society of Health …